CANKADO’s Contribution in upcoming edition of ‘Colloquium Senologie 2021/2022’

Cologne, Germany, 01.07.2021 – The book series ‘Colloquium Senologie’ targets all doctors that devote themselves to the care of breast cancer patients. Together with their team of authors, the editors describe the practice-relevant developments in breast cancer treatment of the previous twelve months. In addition to the state of the art and important findings from international literature, the work also contains reports from important congresses, such as the annual meeting of the American Society for Clinical Oncology (ASCO) or the annual congress of the European Society of Medical Oncology (ESMO).

Prof. Dr. Timo Schinköthe, CEO of CANKADO GmbH, co-authors for the chapter, ‘Digital Health Applications’ in ‘Colloquium Senologie 2021/2022’. The chapter elaborates on the impact of  digital health application’s on cancer care and how such digital applications can support patients to actively participate in their respective therapies.  

The upcoming edition is the tenth release of the book series. This year, the book is launched just four weeks after the ASCO annual conference in 2021 – and it will contain all the practical news from the world’s most important cancer congress.

The launch of the book takes  place in an online event programme, ‘Colloquium Senologie, (www.colloquium-senologie.de), scheduled for July 1st, 2021. As part of the event, participants will have  a chance to win the new manual as an e-book or as a printed edition.

About CANKADO

CANKADO is a digital health platform with a web/app multilingual system. It is registered as a medical device in the European Union and compliant with the FDA classification for Mobile Medical Devices. CANKADO offers digital health solutions and develops new tools specific to the requirements and outputs of each project. It runs with a wide range of clientele that mostly covers pharmaceutical companies and Clinical Research Organisations (CROs). Click here to enquire further information regarding CANKADO’s digital health services.

CANKADO PRO-React Onco is now officially a DiGA (Digitale Gesundheits Anwendung) approved by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). PRO-React Onco is  available for breast cancer patients upon prescription within Germany.

COMPANY DESCRIPTION

CANKADO Service GmbH is headquartered in Germany and has its own presence  in India. Today CANKADO is the leading system for multi-lingual support of patients with chronic diseases in routine care and in clinical trials, also offering various digital health solutions in the areas of cancer, diabetes, cardiology, surgery, cell therapy, psychology, and nutrition.